Molecular characterization of influenza A(H1N1)pdm09 viruses circulating at various geographical locations in India, 2017.


Journal

The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701

Informations de publication

Date de publication:
06 2019
Historique:
entrez: 10 9 2019
pubmed: 10 9 2019
medline: 27 2 2020
Statut: ppublish

Résumé

Influenza virological surveillance is an essential tool for the early detection of novel genetic variants of epidemiologic and clinical significance. This study was aimed to genetically characterize A(H1N1)pdm09 virus circulating in 2017 and to compare it with the global data. The regional/State Viral Research and Diagnostic Laboratories (VRDLs) provided influenza diagnosis for referred clinical samples and shared influenza A(H1N1)pdm09 positives with the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, India, for hemagglutinin (HA) gene phylogenetic analysis. Sites at Manipal, Jaipur and Dibrugarh performed the sequencing and shared the sequence data for analysis. The antiviral susceptibility of influenza viruses was assessed for known molecular marker H275Y at the ICMR-NIV, Pune. All the eight VRDLs had well-established influenza diagnostic facilities and showed increased activity of influenza A(H1N1)pdm09 during 2017. Phylogenetic analysis showed that the viruses from the different regions of the country were similar to A/Michigan/45/2015 strain which was the 2017-2018 recommended vaccine strain and were clustered with the globally circulating clade 6B.1 with signature mutations S84N, S162N and I216T. The clade 6B.1 showed further subgrouping with additional mutations S74R, S164T and I295V; however, there was no significant association between the presence of these mutations and severity of disease due to influenza. All the study viruses were sensitive to oseltamivir. During the study period, all the study sites reported globally circulating A/Michigan/45/2015 vaccine strain of influenza A(H1N1)pdm09 viruses and remained sensitive to oseltamivir. Further genetic and antigenic characterization of influenza viruses is recommended to address public health concerns.

Sections du résumé

Background & objectives
Influenza virological surveillance is an essential tool for the early detection of novel genetic variants of epidemiologic and clinical significance. This study was aimed to genetically characterize A(H1N1)pdm09 virus circulating in 2017 and to compare it with the global data.
Methods
The regional/State Viral Research and Diagnostic Laboratories (VRDLs) provided influenza diagnosis for referred clinical samples and shared influenza A(H1N1)pdm09 positives with the Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, India, for hemagglutinin (HA) gene phylogenetic analysis. Sites at Manipal, Jaipur and Dibrugarh performed the sequencing and shared the sequence data for analysis. The antiviral susceptibility of influenza viruses was assessed for known molecular marker H275Y at the ICMR-NIV, Pune.
Results
All the eight VRDLs had well-established influenza diagnostic facilities and showed increased activity of influenza A(H1N1)pdm09 during 2017. Phylogenetic analysis showed that the viruses from the different regions of the country were similar to A/Michigan/45/2015 strain which was the 2017-2018 recommended vaccine strain and were clustered with the globally circulating clade 6B.1 with signature mutations S84N, S162N and I216T. The clade 6B.1 showed further subgrouping with additional mutations S74R, S164T and I295V; however, there was no significant association between the presence of these mutations and severity of disease due to influenza. All the study viruses were sensitive to oseltamivir.
Interpretation & conclusions
During the study period, all the study sites reported globally circulating A/Michigan/45/2015 vaccine strain of influenza A(H1N1)pdm09 viruses and remained sensitive to oseltamivir. Further genetic and antigenic characterization of influenza viruses is recommended to address public health concerns.

Identifiants

pubmed: 31496532
pii: IndianJMedRes_2019_149_6_783_265967
doi: 10.4103/ijmr.IJMR_925_18
pmc: PMC6755778
doi:

Substances chimiques

Antiviral Agents 0
Influenza Vaccines 0
RNA, Viral 0
Oseltamivir 20O93L6F9H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

783-789

Déclaration de conflit d'intérêts

None

Références

Epidemiol Infect. 2017 Oct;145(13):2656-2665
pubmed: 28768557
Indian J Med Res. 2014 Aug;140(2):244-51
pubmed: 25297358
Epidemiol Infect. 2017 Jul;145(9):1898-1909
pubmed: 28367767
Emerg Infect Dis. 2014 Oct;20(10):1723-6
pubmed: 25279651
PLoS One. 2010 Mar 15;5(3):e9693
pubmed: 20300625
J Med Virol. 2018 Mar;90(3):447-455
pubmed: 29073730
PLoS One. 2015 May 04;10(5):e0124122
pubmed: 25938466
Infect Genet Evol. 2011 Jul;11(5):997-1005
pubmed: 21457796
Cell. 1982 Dec;31(2 Pt 1):417-27
pubmed: 6186384
WHO South East Asia J Public Health. 2013 Jul-Dec;2(3):181-183
pubmed: 28615594
PLoS One. 2010 May 07;5(5):e10540
pubmed: 20479875

Auteurs

Varsha Potdar (V)

Influenza Group, ICMR-National Institute of Virology, Pune, India.

Neetu Vijay (N)

Department of Health Research, Ministry of Health & Family Welfare, Government of India, New Delhi, India.

Nivedita Gupta (N)

Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, Headquarters, New Delhi, India.

G Arunkumar (G)

Manipal Institute of Virology, Manipal Academy of Higher Education (Deemed to be University), Manipal, India.

Bishwajyoti Borkakoty (B)

ICMR-Regional Medical Research Center, Dibrugarh, India.

Bharti Malhotra (B)

Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India.

Debajit Rabha (D)

Department of Microbiology, Guwahati Medical College, Guwahati, India.

Dilip Hinge (D)

Influenza Group, ICMR-National Institute of Virology, Pune, India.

Harmanmeet Kaur (H)

Department of Health Research, Ministry of Health & Family Welfare, Government of India, New Delhi, India.

Mandeep Chadha (M)

Influenza Group, ICMR-National Institute of Virology, Pune, India.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH